OncRef
Skip to newsletter content
|
RCCOctober 2026
0:00 / 3:18
Renal Cell Carcinoma — Monthly Compass
Oct 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in renal cell carcinoma this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
renal cell carcinoma updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • On September 24, 2026, the FDA approved belzutifan (Welireg) plus lenvatinib (Lenvima) for adults with advanced RCC with a clear cell component after PD‑1/PD‑L1 therapy, with the decision supported by LITESPARK‑011 and accompanied by labeled dosing details and clinical context.
  • Key Clinical Development Updates
    • Xencor selected 400 mcg/kg IV as the RP3D for the ENPP3 × CD3 bispecific XmAb819 in advanced clear cell RCC and plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC subgroups in 1H 2027, anticipating a registration‑enabling monotherapy study by end of 2027.
    • Summit Therapeutics initiated site openings for SMT112‑216, a randomized multiregional Phase II study of ivonescimab‑based regimens in previously untreated advanced ccRCC across the U.S. and China, while reiterating that the FDA accepted its ivonescimab BLA for NSCLC in January 2026 with a PDUFA goal date of November 14, 2026.
  • Important Clinical Trial Publications
    • The final LITESPARK‑011 readout favored belzutifan + lenvatinib over cabozantinib after anti–PD‑(L)1 therapy by sustaining PFS/ORR advantages without a statistically significant OS benefit and included HRQoL analyses to inform benefit–risk in routine care.
  • Key Conference Updates
    • At ESMO 2026 (October 23–27, Madrid), addition of either belzutifan or CTLA‑4 blockade (quavonlimab/MK‑1308A) to pembrolizumab + lenvatinib did not improve PFS/OS and increased AE‑related discontinuations, reinforcing PD‑1 + VEGF TKI doublets as the global first‑line default in ccRCC.
    • ESMO presentations underscored maturation of earlier intervention and precision selection, with perioperative pembrolizumab plus MDT (PE‑PE) improving relapse‑free survival, final KEYNOTE‑564 sustaining DFS/OS benefits for adjuvant pembrolizumab, and a blood‑based proteomic classifier distinguishing candidates for ICI–TKI versus dual‑IO in first‑line mRCC.
  • Emerging Themes & Macro‑Trends
    • Post‑IO adoption of belzutifan + lenvatinib is likely to increase given consistent PFS/ORR gains and ESMO visibility, while bispecifics are positioned for randomized confirmation rather than immediate practice change.
    • Strategic investment is concentrating on HIF‑2α–VEGF combinations in the post‑IO setting and selectively advancing RCC‑specific bispecifics with clear differentiation and manageable immune toxicities.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-10-01 and 2026-10-31 about renal cell carcinoma.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Xencor reported Phase 1 dose-selection data for the ENPP3 x CD3 bispecific XmAb819 in advanced clear cell RCC, selecting 400 mcg/kg IV as the proposed RP3D. The company said it plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC subgroups in 1H 2027 and anticipates a potential registration-enabling monotherapy study by the end of 2027. ¹ (read more)
  • Summit Therapeutics announced site openings for SMT112-216, a randomized multiregional Phase II study of ivonescimab-based regimens in previously untreated advanced ccRCC (U.S. and China). In the same release, Summit reiterated that the FDA accepted its ivonescimab BLA for NSCLC in January 2026 with a PDUFA goal date of November 14, 2026, underscoring ongoing U.S. regulatory review for the program as it expands into RCC. ² (read more)
  • Targeted Oncology highlighted that on September 24, 2026, the FDA approved belzutifan (Welireg) plus lenvatinib (Lenvima) for adults with advanced RCC with a clear cell component after PD‑1/PD‑L1 therapy. The article summarizes the LITESPARK-011 data supporting approval and provides labeled dosing details and clinical context. ³ (read more)
Conference
Major Conference Updates
Conference Information
  • ESMO Congress 2026; Madrid, Spain; October 23–27, 2026. (read more)
  • Overall sentiment: Frontline triplet intensification underwhelmed, cementing PD-1 + VEGF TKI doublets; momentum shifted to post–PD-(L)1 sequencing, emergent bispecifics, and earlier/interception strategies. (read more)
  • Theme 1: Triplet Intensification Fails in 1L ccRCC
    • Significance: Adding a third agent to pembrolizumab + lenvatinib did not improve outcomes, discouraging costly/toxic escalation in the frontline. (read more)
    • Mechanism insights / clinical impact: Neither HIF‑2α inhibition (belzutifan) nor CTLA‑4 blockade (quavonlimab, coformulated as MK‑1308A) enhanced PFS/OS; higher AE‑related discontinuations eroded exposure—reinforcing pembrolizumab + lenvatinib as standard. (read more)
    • Patient populations affected: Untreated advanced clear cell RCC across IMDC risk groups; global practice should maintain PD‑1 + VEGF TKI doublet as default first line. (read more)
  • Theme 2: Post‑IO Sequencing with HIF‑2α + VEGF TKI
    • Significance: Final LITESPARK‑011 readout supports belzutifan + lenvatinib over cabozantinib after anti–PD‑(L)1, guiding second‑line sequencing where VEGF TKI alone has dominated. (read more)
    • Mechanism insights / clinical impact: Dual hypoxia (HIF‑2α) and angiogenesis blockade sustained PFS/ORR advantages without statistically significant OS gain; session included HRQoL analyses, informing benefit–risk in routine care. (read more)
    • Patient populations affected: Advanced ccRCC progressing after PD‑(L)1 therapy; broad international applicability in post‑IO settings. (read more)
  • Theme 3: Bispecifics and T‑Cell Engagers Emerge
    • Significance: Early activity from tumor‑targeted T‑cell engagement and PD‑1/VEGF co‑targeting signals a pipeline pivot beyond classic ICI+TKI pairings. (read more)
    • Mechanism insights / clinical impact: XmAb819 (ENPP3 × CD3, 2+1 format) selected an IV RP3D with promising response durability; ivonescimab (AK112) unified PD‑1 blockade and anti‑angiogenesis within a single molecule, simplifying delivery and potentially AE management—both require randomized validation. (read more)
    • Patient populations affected: Heavily pretreated advanced ccRCC (XmAb819) and IMDC favorable‑risk 1L aRCC (ivonescimab) in multinational programs, with prospective expansion to ENPP3+ tumors. (read more)
  • Theme 4: Earlier Intervention and Precision Selection
    • Significance: Perioperative and adjuvant strategies matured, while blood‑based models for TKI sensitivity surfaced to individualize first‑line choices. (read more)
    • Mechanism insights / clinical impact: PE‑PE showed improved relapse‑free survival with perioperative pembrolizumab + MDT; final KEYNOTE‑564 sustained DFS/OS benefits for adjuvant pembrolizumab; proteomic classifier distinguished patients more likely to benefit from ICI–TKI vs dual‑IO. (read more)
    • Patient populations affected: Oligometastatic RCC candidates for MDT, resected high‑risk ccRCC, and mRCC needing biomarker‑guided 1L regimen selection. (read more)
  • Significance
    • Expected clinical or translational readouts: Registration‑enabling study planning for XmAb819 and sponsor‑stated discussions of potential accelerated approval in defined ccRCC subgroups (1H2027); additional bispecific RCC datasets anticipated. (investors.xencor.com) (read more)
    • Regulatory or policy implications: Frontline SoC remains pembrolizumab + lenvatinib; post‑IO adoption of belzutifan + lenvatinib likely to increase given consistent PFS/ORR gains and ESMO visibility. (read more)
    • Potential shifts in standard of care: De‑prioritize 1L triplets; emphasize optimized sequencing and early‑stage ICI deployment; bispecifics poised for randomized confirmation rather than immediate practice change. (read more)
    • Strategic implications: Focus investment on HIF‑2α–VEGF combinations post‑IO, accelerate biomarker platforms that steer ICI–TKI vs dual‑IO, and selectively advance RCC‑specific bispecifics with clear differentiation and manageable immune toxicities. (read more)
Publications Related to Approved Drugs
Summary of Research: Health-Related Quality-of-Life Profile and Clinical Outcomes in First-Line Advanced Renal Cell Carcinoma: A Modeling Analysis Based on the CheckMate 9ER Study. A post hoc analysis of the phase 3 CheckMate 9ER study demonstrated a significant link between early patient-reported outcomes and clinical efficacy, where early worsening of bone pain or sleep quality was associated with an increased risk of mortality. The analysis identified a "limited symptoms" patient profile, more common in those receiving cabozantinib plus nivolumab, which was predictive of a longer treatment duration and a lower likelihood of disease progression, reinforcing the value of HRQoL in optimizing treatment strategies. ()
Summary of Research: Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy. In a post hoc analysis of the CheckMate 9ER study, a two-stage estimation model was used to adjust for the confounding effects of subsequent therapies on overall survival (OS). After adjustment, the OS benefit of first-line cabozantinib plus nivolumab over sunitinib was substantially greater (HR 0.53) than in the unadjusted analysis (HR 0.79), providing stronger evidence for its superior efficacy as a first-line standard of care in advanced renal cell carcinoma. ()
New Publications Related to Drugs in Clinical Trial Development
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study. The addition of either the HIF-2α inhibitor belzutifan or the CTLA-4 inhibitor quavonlimab to the standard first-line regimen of pembrolizumab plus lenvatinib failed to improve progression-free or overall survival in patients with advanced renal-cell carcinoma. These triplet combinations resulted in higher rates of adverse events leading to drug discontinuation, reinforcing the doublet as the established standard of care. ()
Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy. In the final analysis for patients with advanced renal cell carcinoma post-immunotherapy, the combination of belzutifan and lenvatinib continued to demonstrate superior progression-free survival, objective response rate, and duration of response compared to cabozantinib. Although the overall survival benefit did not achieve statistical significance, these robust findings support the combination as a strong treatment option in this second-line setting. ()
Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial. A novel regimen alternating pazopanib with bevacizumab showed promising antitumor activity in treatment-naive metastatic clear-cell renal cell carcinoma, achieving a median progression-free survival of 24.8 months, primarily in a favorable-risk population. This phase 1/2 study established a safe dose and schedule, suggesting a potential new strategy that now requires validation in a phase 3 randomized trial. ()
A phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M). In the Pediatric MATCH trial, the farnesyl transferase inhibitor tipifarnib showed limited single-agent efficacy in children and young adults with refractory solid tumors harboring HRAS mutations, with no objective responses observed. While the drug's safety profile was acceptable, the lack of clinical benefit suggests that monotherapy is insufficient for this biomarker-selected pediatric population. ()
Nivolumab and cabozantinib in people with HIV and advanced solid tumors: a pilot trial and systematic review. The combination of nivolumab and cabozantinib was found to be safe and feasible in people living with HIV (PWH) with advanced solid tumors, with no adverse impact on HIV virologic control. This pilot trial observed durable disease stabilization in some heavily pretreated participants, supporting the need for larger studies of this combination in this underrepresented patient population. ()
A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma. Combination regimens of the bispecific antibody tobemstomig (anti-PD-1/LAG-3) with axitinib, with or without the anti-TIGIT antibody tiragolumab, did not demonstrate a meaningful efficacy improvement over the standard of care (pembrolizumab plus axitinib) for untreated advanced clear-cell renal cell carcinoma. The study was terminated for futility as the investigational arms were associated with increased toxicity without a corresponding clinical benefit. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in renal cell carcinoma updated from 2026-10-01 to 2026-10-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation----1-1
Not Yet Recruiting115-2-9
Recruiting121313-2242
Available-------
Approved for Marketing-------
Active, Not Recruiting11511-6-33
Completed---1--1
Total241929111286
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Belzutifan NCT02974738 ACTIVE_NOT_RECRUITING A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors 2026-11-30
: Ziv-Aflibercept, : Pembrolizumab NCT02298959 ACTIVE_NOT_RECRUITING A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors 2027-01-20
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
: Nivolumab, Axitinib NCT03595124 ACTIVE_NOT_RECRUITING A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups 2026-11-13
Ibuprofen, Acetaminophen, Hydromorphone, Oxycodone, Ketorolac NCT05842044 ACTIVE_NOT_RECRUITING NSAID Use After Robotic Partial Nephrectomy (No-PAIN): a Randomized, Controlled Trial 2026-12-31
: Nivolumab, Relatlimab NCT04953104 ACTIVE_NOT_RECRUITING A Phase II Clinical Trial to Investigate ARID1A and/or KDM6A Mutation and CXCL13 Expression in the Pre-treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Urothelial Cancer 2026-12-31
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Everolimus, Belzutifan NCT04195750 ACTIVE_NOT_RECRUITING An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies 2026-10-14
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.